In recent trials, treatment with sodium-glucose cotransporter-2 inhibitors reduced the risk of progressive kidney disease, kidney failure, or death.12,13 This sizable subgroup of patients with suboptimal control could also qualify for other recently approved IgA nephropathy treatments and/or referral for disease-specific clinical trials.14 This evidence concerns the gene SLC5A2 and IgA glomerulonephritis.